Experiences of injectable contraceptive users in an urban setting
References (21)
- et al.
Acceptability of injectable contraceptives in Assiut Egypt
Contraception
(1988) - et al.
Contraceptive use—Efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days
Fertil Steril
(1973) - et al.
One-year experience with subdermal contraceptive implants in the United States
Contraception
(1993) - et al.
Preliminary experience with Norplant in an inner-city population
Contraception
(1993) - et al.
Three year experience with Norplant subdermal contraception
Fertil Steril
(1983) Epidemiology of unintended pregnancy and contraceptive use
Am J Obstet Gynecol
(1994)Contraception with subdermal levonorgestrel implants as an alternative to surgical contraception at Ilorin Nigeria
Int J Gynaecol Obstet
(1991)- et al.
Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable conraceptives
Br J Obstet Gynaecol
(1981) Development Research Training in Human Reproduction; Task Force on LongActing Agents for the Regulation of Fertility. Multinational comparative
Final report. Contraception
(1983)- et al.
Depo-Provera use in an Australian metropolitan practice
Med J Aust
(1994)
Cited by (104)
Progesterone, reproduction, and psychiatric illness
2020, Best Practice and Research: Clinical Obstetrics and GynaecologyCitation Excerpt :Injectable: Depot medroxyprogesterone acetate (DMPA) was the first non-oral formulation of hormonal contraception available in the United States, and early studies showing an association between DMPA and mood symptoms led to the Food and Drug Administration (FDA) warnings about contraception and mood. The results from two early prospective descriptive studies published in 1996 and 1997 reported high discontinuation rates at 1 year (47% and 71%, respectively), with 6% (N = 18) of those stopping DMPA citing depression as the reason for discontinuation and up to 9% reporting ongoing depressive symptoms at 3 months following DMPA initiation [79,80]. Next, two studies by Westhoff and colleagues (1998) assessed for symptoms of depression with DMPA, but did not find a significant association [81,82].
Reproductive and hormonal factors and the risk for osteoporosis
2020, Marcus and Feldman’s OsteoporosisEffectiveness and use of hormonal contraceptives (except for intrauterine devices): CNGOF Contraception Guidelines
2018, Gynecologie Obstetrique Fertilite et SenologieCanadian Contraception Consensus (part 3 of 4): Chapter 8 - Progestin-only contraception
2016, Journal of Obstetrics and Gynaecology CanadaCanadian Contraception Consensus (Part 3 of 4): Chapter 8 - Progestin-Only Contraception
2016, Journal of Obstetrics and Gynaecology Canada